Postdoctoral Scholar – Tumor Immunology

At Moffitt Cancer Center, we strive to be the leader in understanding the complexity of cancer and applying these insights to contribute to the prevention and cure of cancer. Our diverse team of over 9,000 are dedicated to serving our patients and creating a workspace where every individual is recognized and appreciated. For this reason, Moffitt has been recognized on the 2023 Forbes list of America’s Best Large Employers and America’s Best Employers for Women, Computerworld magazine’s list of 100 Best Places to Work in Information Technology, DiversityInc Top Hospitals & Health Systems and continually named one of the Tampa Bay Time’s Top Workplace. Additionally, Moffitt is proud to have earned the prestigious Magnet® designation in recognition of its nursing excellence. Moffitt is a National Cancer Institute-designated Comprehensive Cancer Center based in Florida, and the leading cancer hospital in both Florida and the Southeast. We are a top 10 nationally ranked cancer center by Newsweek and have been nationally ranked by U.S. News & World Report since 1999.
Working at Moffitt is both a career and a mission: to contribute to the prevention and cure of cancer. Join our committed team and help shape the future we envision.

Summary

Postdoctoral Scholar – Tumor Immunology

The Haura lab has an opening for a postdoctoral scholar in tumor immunology and adoptive cell therapy research. Moffitt’s trajectory is to become a worldwide leader in cell therapy for cancer. Our lab uses an interdisciplinary approach spanning immune biology and proteogenomics to functionally characterize responses to immune therapy. We are looking for a highly motivated and independent postdoctoral research fellow who is interested in working on a project related to tumor neoantigens that predict response to tumor infiltrating lymphocytes (TIL) trial therapy in lung cancer patients, recently published in Nature Medicine (https://www.nature.com/articles/s41591-021-01462-y)

Position Highlights:

The candidate will have immediate access to rich array of patient samples including resected tumors and tumor cell suspensions, and apheresis products and will join a productive, energetic team of immunologists, bioinformaticians, clinicians, surgeons, and protein researchers within our group.

The Ideal Candidate:

Successful candidates will have a publication track record demonstrating a strong background in tumor immunology and/or immune-therapy; with an interest in translational research. Prior experience is required with some of the following techniques: high-throughput screening, lymphocyte cell culture (T cells and dendritic cells), ELISA/ELISpot assay, nucleic acids/protein extraction, flow cytometry (FACS). Expertise in molecular biology (cloning, plasmid purification) and adoptive cell therapy is highly preferred. Candidates with experience in validating neoantigens in model systems will be given priority.

Responsibilities:

This individual will design, conduct and interpret correlative experiments using human samples from accruing immunotherapy clinical trials, in particular a trial using adoptive cell transfer of tumor infiltrating lymphocytes (TIL). This individual will identify and validate predicted neoantigens from lung cancer immunotherapy trials using established and novel functional assays.

Credentials and Qualifications:

M.D. or PhD in Molecular Biology, Immunology, Biochemistry, or relevant field.

Interested applicants should send their current CV with recent publications and contact information for three references to Dr. Ben Creelan at Ben.Creelan@moffitt.org

Moffitt Cancer Center is a premier cancer research institution in the United States. Built in an attractive location, it is the only NCI-designated cancer center in Florida and one of the top institutions in systems medicine and personalized cancer therapy. Moffitt features a number of high-quality core facilities equipped with state-of-the-art instrumentation and a cluster of expertise particularly in adoptive cell therapies.